Mariano Esteban’s vaccine at the CSIC focuses on new variants
The Higher Council for Scientific Research (CSIC) and Biofabri have decided to withdraw the application to the Spanish Medicines Agency (AEMPS) to carry out a clinical trial of its vaccine against COVID-19, “given the difficulties in completing it in Spain, given the very high percentage of the vaccinated population and the incidence of the new omicron variant”.
In any case, CSIC and Biofabri have made the decision that research on this vaccine, headed by researchers Mariano Esteban and Juan García Arriaza at the National Center for Biotechnology (CNB-CSIC), “continues to adapt its vaccine model to the new variants. “After analyzing the current vaccination situation against SARS-CoV-2 virus infection in Spain, We have assessed the window of opportunity to carry out this clinical trial, and we have decided to withdraw the evaluation dossier that we have presented to the AEMPS”, as confirmed by CSIC sources to Europa Press, after the information provided by Medical Writing.
–
